CHICAGO — The American Medical Association (AMA) today commended the Food and Drug Administration (FDA) and the Federal Trade Commission for issuing joint warning letters to the marketers and distributors of 12 opioid cessation products for illegally marketing unapproved products with claims about their ability to help in the treatment of opioid addiction and withdrawal. The following statement is attributable to Patrice A. Harris, M.D., chair of the AMA Opioid Task Force.
“This aggressive and timely action will save lives. Our patients with substance use disorder need safe and effective treatment, not sham treatments that fleece them and prey on the stigma surrounding this disorder.
“Physicians have several tools to help patients overcome an opioid addiction. If patients are drawn to unapproved treatments, they face delays — and even death — by the time they realize the ineffectiveness of these heavily promoted ‘treatments.’
“It should go without saying that people with substance use disorders are vulnerable and easily victimized by promises of a quick and painless recovery. Our patients have enough obstacles in accessing treatment, whether it is prior authorization, insurance issues or a shortage of treatment options. Thanks to the FDA and FTC action, they have one fewer obstacle.”
Media Contact:
About the American Medical Association
The American Medical Association is the physicians’ powerful ally in patient care. As the only medical association that convenes 190+ state and specialty medical societies and other critical stakeholders, the AMA represents physicians with a unified voice to all key players in health care. The AMA leverages its strength by removing the obstacles that interfere with patient care, leading the charge to prevent chronic disease and confront public health crises and, driving the future of medicine to tackle the biggest challenges in health care.
